65 related articles for article (PubMed ID: 23359479)
1. Identification of transcription factors associated with castration-resistance: is the serum responsive factor a potential therapeutic target?
Prencipe M; Madden SF; O'Neill A; O'Hurley G; Culhane A; O'Connor D; Klocker H; Kay EW; Gallagher WM; Watson WR
Prostate; 2013 May; 73(7):743-53. PubMed ID: 23359479
[TBL] [Abstract][Full Text] [Related]
2. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
3. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
[TBL] [Abstract][Full Text] [Related]
4. Relationship between serum response factor and androgen receptor in prostate cancer.
Prencipe M; O'Neill A; O'Hurley G; Nguyen LK; Fabre A; Bjartell A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2015 Nov; 75(15):1704-17. PubMed ID: 26250344
[TBL] [Abstract][Full Text] [Related]
5. Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.
Kiyama S; Morrison K; Zellweger T; Akbari M; Cox M; Yu D; Miyake H; Gleave ME
Cancer Res; 2003 Jul; 63(13):3575-84. PubMed ID: 12839944
[TBL] [Abstract][Full Text] [Related]
6. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.
Pootrakul L; Datar RH; Shi SR; Cai J; Hawes D; Groshen SG; Lee AS; Cote RJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5987-93. PubMed ID: 17062670
[TBL] [Abstract][Full Text] [Related]
7. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
8. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME
Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589
[TBL] [Abstract][Full Text] [Related]
9. Regulation of global gene expression in the bone marrow microenvironment by androgen: androgen ablation increases insulin-like growth factor binding protein-5 expression.
Xu C; Graf LF; Fazli L; Coleman IM; Mauldin DE; Li D; Nelson PS; Gleave M; Plymate SR; Cox ME; Torok-Storb BJ; Knudsen BS
Prostate; 2007 Nov; 67(15):1621-9. PubMed ID: 17823924
[TBL] [Abstract][Full Text] [Related]
10. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.
O'Hurley G; Prencipe M; Lundon D; O'Neill A; Boyce S; O'Grady A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2014 Feb; 74(3):306-13. PubMed ID: 24249383
[TBL] [Abstract][Full Text] [Related]
11. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue.
Joseph IB; Nelson JB; Denmeade SR; Isaacs JT
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2507-11. PubMed ID: 9815654
[TBL] [Abstract][Full Text] [Related]
12. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
[TBL] [Abstract][Full Text] [Related]
13. Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
Yano S; Matsuyama H; Hirata H; Inoue R; Matsumoto H; Ohmi C; Miura K; Shirai M; Iizuka N; Naito K
Oncol Rep; 2006 Jun; 15(6):1453-60. PubMed ID: 16685379
[TBL] [Abstract][Full Text] [Related]
14. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
15. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis.
Rocchi P; Beraldi E; Ettinger S; Fazli L; Vessella RL; Nelson C; Gleave M
Cancer Res; 2005 Dec; 65(23):11083-93. PubMed ID: 16322258
[TBL] [Abstract][Full Text] [Related]
16. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.
Miyake H; Pollak M; Gleave ME
Cancer Res; 2000 Jun; 60(11):3058-64. PubMed ID: 10850457
[TBL] [Abstract][Full Text] [Related]
17. Role of cationic channel TRPV2 in promoting prostate cancer migration and progression to androgen resistance.
Monet M; Lehen'kyi V; Gackiere F; Firlej V; Vandenberghe M; Roudbaraki M; Gkika D; Pourtier A; Bidaux G; Slomianny C; Delcourt P; Rassendren F; Bergerat JP; Ceraline J; Cabon F; Humez S; Prevarskaya N
Cancer Res; 2010 Feb; 70(3):1225-35. PubMed ID: 20103638
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of the mouse prostate after castration and hormone replacement: implication of H-cadherin in prostate tumorigenesis.
Wang XD; Wang BE; Soriano R; Zha J; Zhang Z; Modrusan Z; Cunha GR; Gao WQ
Differentiation; 2007 Mar; 75(3):219-34. PubMed ID: 17288544
[TBL] [Abstract][Full Text] [Related]
19. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.
Terada N; Shimizu Y; Kamba T; Inoue T; Maeno A; Kobayashi T; Nakamura E; Kamoto T; Kanaji T; Maruyama T; Mikami Y; Toda Y; Matsuoka T; Okuno Y; Tsujimoto G; Narumiya S; Ogawa O
Cancer Res; 2010 Feb; 70(4):1606-15. PubMed ID: 20145136
[TBL] [Abstract][Full Text] [Related]
20. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
Heemers HV; Regan KM; Dehm SM; Tindall DJ
Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]